Stay up-to-date on the latest news from the CIBMTR.

Recent News

Joint Letters Regarding Immunocompromised Patients and COVID-19 Funding 

June 21, 2022: The undersigned organizations, all committed to caring for the millions of Americans with impaired immune systems, seek your support to keep this vulnerable population a priority as you consider additional COVID-19 relief funding by prioritizing therapeutic purchasing and research for new therapeutics, such as prophylactic therapies and antiviral medications. Our immunocompromised/suppressed patients are at a higher risk for serious COVID-19 complications and mortality. As COVID-19 continues to evolve, presenting new variants and surges every few months, further federal investment is needed not only to secure an adequate supply of current therapeutics, but to also support the next generation of vaccines and treatments to protect those at highest risk.

Read more:

Letter to the United States Senate

Letter to the U.S. House of Representatives

Signed:

The Center for International Blood and Marrow Transplant Research Celebrates 50th Anniversary During the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

April 22, 2022 – 2022 marks the 50th anniversary of the Center for International Blood and Marrow Transplant Research® (CIBMTR®). Cellular therapy has come a long way from its roots in the Cold War of the 1950s, from an experimental treatment for radiation sickness to a standard therapy for leukemia, lymphoma and sickle cell disease. Now, cellular therapy includes both blood and marrow transplantation and other adoptive cellular therapies.

The Center for International Blood and Marrow Transplant Research Named Recipient of 2021 Amazon Web Services Imagine Grant for Nonprofits

November 30, 2021 – The Center for International Blood and Marrow Transplant Research (CIBMTR) today announced it has been selected as a recipient of the 2021 Amazon Web Services (AWS) Imagine Grant, a public grant opportunity open to registered 501(c) nonprofit organizations in the United States (U.S.) who use technology to solve the world’s most pressing challenges. The grant will support the CIBMTR’s efforts to leverage technology advances to better acquire data and more quickly apply research and learning to accelerate the transformation of patient data into improved patient outcomes.

The Center for International Blood and Marrow Transplant Research (CIBMTR) Launches Study of COVID-19 Vaccine Immunogenicity in Patients With Hematological Malignancies Who Have Received Cellular Therapy

May 18, 2021 – The CIBMTR® (Center for International Blood and Marrow Transplant Research®) announces the launch of a large observational study, done in collaboration with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) to understand the safety, efficacy, and durability of responses to COVID-19 vaccines in patients with hematological malignancies and non-malignant blood diseases who have received hematopoietic cell transplantation (HCT) or cellular therapies. The study is supported by National Marrow Donor Program (NMDP)/Be The Match®, The Leukemia & Lymphoma Society (LLS), the National Heart, Lung, and Blood Institute, the National Cancer Institute, the Fred Hutchinson Cancer Research Center, the Multiple Myeloma Research Foundation (MMRF), American Society for Transplantation and Cellular Therapy (ASTCT), and LabCorp.

Results of multicenter clinical trial sponsored by National Marrow Donor Program/Be The Match to be published in Journal of Clinical Oncology

April 27, 2021 – The CIBMTR® (Center for International Blood & Marrow Transplant Research®) manuscript entitled, "A National Marrow Donor Program Sponsored Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide," has been published in the Journal of Clinical Oncology.  

CIBMTR Study Shows, Compared to the Public, People Who Had a Blood or Marrow Transplant (BMT) Have Higher Risk of Dying of COVID-19 
January 19, 2021: People who have had blood or marrow transplant (BMT) may be particularly vulnerable to dying from COVID-19, according to a study published today in the journal, Lancet Haematology, using data reported to the CIBMTR® (Center for International Blood and Marrow Transplant Research), a research collaboration between the National Marrow Donor Program® (NMDP)/Be The Match® and the Medical College of Wisconsin (MCW). 

DBtC now includes CAR-T Visualizations & REMS (Risk Evaluation Mitigation Strategy) Data

October 31, 2020: The Center for International Blood and Marrow Transplant Research (CIBMTR) launched an upgrade to the DBtC (Data Back to Centers) application—available via the CIBMTR Portal—that includes both more data and new features. DBtC is a part of the suite of applications that provides self-service, on-demand data, and analytics to participating centers. For the first time, enhancements to DBtC enable centers that submit data on chimeric antigen receptor T cells (CAR-T) to the CIBMTR to visualize CAR-T information and HCT information.

CIBMTR Clinical Outcomes Registry Automates Data Collection to Accelerate Life-Saving Research

October 22, 2020: The CIBMTR® (Center for International Blood and Marrow Transplant Research®), a research collaboration between the National Marrow Donor Program® (NMDP)/Be The Match® and the Medical College of Wisconsin, is pioneering the automation of transmitting electronic medical record data from its research network partners to its outcomes registry. 

CIBMTR completes enrollment in Yescarta® long-term post-marketing safety study, 2 years ahead of schedule 

September 8, 2020: The CIBMTR® (Center for International Blood and Marrow Transplant Research®) today announced that it has reached a study enrollment goal 2 years early, and 1,500 patients have now enrolled in the post-marketing safety study for Yescarta® (axicabtagene ciloleucel). The study is part of a collaboration with Kite, a Gilead Company. 

Joint Statement from ASTCT, CIBMTR, FACT, ISCT, and EBMT 

June 8, 2020: Racism has no place in our society and profession. The American Society for Transplantation and Cellular Therapy (ASTCT), the Center for International Blood and Marrow Transplant Research (CIBMTR), Foundation for the Accreditation of Cellular Therapy (FACT), the International Society for Cell & Gene Therapy (ISCT), and the European Society for Blood and Marrow Transplant (EBMT), all find these acts of racism reprehensible and inexcusable. This cannot be ignored any longer by the global community and our respective organizations.

New Leaders at ASTCT and CIBMTR Provide Guidelines and Measures for Combating COVID-19 and Protecting Transplant Patients

May 22, 2020: The American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR) outlined today their guidelines and measures for combating the spread of COVID-19, while providing protection to transplant patients. The guidelines and measures include new practices for data collection, sharing of information, and administrative relief for facilities impacted by COVID-19 precautions.

CIBMTR® announces real world data effort to accelerate breakthroughs that transform patient experiences in cellular therapy with IQVIA

February 19, 2020: The CIBMTR® (Center for International Blood and Marrow Transplant Research®) today announced the selection of IQVIA as it seeks to expand the value real world data can bring to patients, through systematic investigation to generate real world evidence. IQVIA (NYSE: IQV) is a company known worldwide for its expertise in building technology solutions customized for global research networks engaged in complex data exchange for clinical outcomes registries.

Kite and the CIBMTR® Present Positive Findings From Real-World Use of  Yescarta® (Axicabtagene  Ciloleucel) in Relapsed or Refractory Large B-Cell  Lymphoma

December 9, 2019: Kite, a Gilead Company (Nasdaq: GILD), and the CIBMTR® (Center for International Blood and Marrow Transplant Research®), the research collaboration between the National Marrow Donor Program® (NMDP)/Be The Match® and the Medical College of Wisconsin (MCW), today announced findings from an ongoing post-marketing study evaluating the safety and efficacy of Yescarta® (axicabtagene ciloleucel) in adult patients with relapsed or refractory large B-cell lymphoma.  In this analysis, efficacy and safety of Yescarta were comparable to that observed in the ZUMA-1 trial, despite a larger proportion of older, more difficult-to-treat patients in the real-world setting. The findings were presented today at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition, held in Orlando from December 7–10, 2019. 

Gamida Cell and the CIBMTR Announce Collaboration to Advance Research for Life-Saving Cellular Therapy

September 11, 2019: Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, and the CIBMTR® (Center for International Blood and Marrow Transplant Research®) today announced the entry into a research agreement to collect and analyze health outcomes data in patients with hematologic malignancies who receive an allogeneic hematopoietic stem cell transplant (HSCT, or bone marrow transplant) from various donor sources. The CIBMTR is an organization that collaborates with the global scientific community to advance hematopoietic cell transplantation (HCT) and cellular therapy worldwide. 

CIBMTR to Track Long-Term Outcomes Data for Kymriah®

September 14, 2018: A new collaboration focused on tracking long-term outcomes of patients treated with chimeric antigen receptor T-cell (CAR-T) therapies has been established between the CIBMTR® (Center for International Blood and Marrow Transplant Research), and Novartis. Under the terms of the collaboration, CIBMTR will collect long-term safety and efficacy data from patients (pediatrics and adults) treated with Kymriah® (tisagenlecleucel) who agree to participate in the CIBMTR registry for cellular therapy.

CIBMTR Announces Collaboration with Kite to Track Long-Term Outcomes Data for YESCARTA®

May 17, 2018: A new collaboration focused on tracking long-term outcomes of patients treated with chimeric antigen receptor T cell (CAR T) therapies is formed between the CIBMTR® (Center for International Blood and Marrow Transplant Research), and Kite, a Gilead Company. CIBMTR is an organization that collaborates with the global scientific community to advance hematopoietic cell transplantation (HCT) and cellular therapy worldwide. Under the terms of the agreement, CIBMTR will collect and analyze long-term safety and efficacy data for YESCARTA® in a commercial setting.